Apollo Health Ventures
Longevity-focused venture capital fund investing in companies developing therapeutics that target the fundamental biology of aging. Pioneer in connecting traditional VC with decentralized science (DeSci) through partnerships with VitaDAO.
Location
Dusseldorf, Germany / Boston, USA
Founded
2015
AUM
$300M+
Investment Range
$5M - $25M
Portfolio Companies
15
Focus
biotech-focused
Fund Stages
seed, series-a, series-b
Investment Thesis
Apollo Health Ventures focuses exclusively on longevity biotechnology, investing in companies that target the fundamental mechanisms of aging to prevent and treat age-related diseases. They take a thesis-driven approach based on the biology of aging and partner with leading scientists in the field.
Team
Partners / Managing Directors (Health & Bio Focus)
- Patrick Burgermeister - Co-Founder & Managing Partner
- Alexandra Bause - Co-Founder & Partner
- Krister Brommesson - Partner
Other Key Team Members
- James Peyer, PhD - CEO & Managing Partner
Focus Areas
- Longevity/Aging Biology
- Cellular Senescence
- Autophagy
- Neurodegeneration
- Metabolic Disease
- Epigenetics
- Decentralized Science (DeSci)
Notable Exits
- Portfolio companies advancing through clinical development
- Partnership with VitaDAO and Molecule AG
Portfolio Companies
- Therini Bio ($39M Series A, 2025, neurodegenerative disease)
- HAYA Therapeutics ($65M Series A, 2025, precision RNA-guided medicines)
- Auron Therapeutics ($27M Series B, 2025, precision oncology)
- Booster Therapeutics ($15M seed, 2024, toxic accumulations)
- Cleara Biotech (cellular senescence targeting)
- Samsara Therapeutics (autophagy enhancer platform)
- Aeovian Pharmaceuticals (mTORC1 pathway modulation)
Sources
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| Therini Bio | Boston, Massachusetts, USA | 2022 | therapeuticsbiotech+3 |
| HAYA Therapeutics | Lausanne, Switzerland | 2015 | therapeuticsbiotech+3 |
| Auron Therapeutics | New York, New York, USA | 2019 | biotechoncology+3 |
| Booster Therapeutics | Copenhagen, Denmark | 2024 | biotechtherapeutics+3 |
| Aeovian Pharmaceuticals | - | - | therapeuticsbiotech+1 |
| Cleara Biotech | Utrecht, Netherlands | 2017 | therapeuticsbiotech+3 |
| Samsara Therapeutics | Oxford, United Kingdom | 2019 | therapeuticsbiotech+3 |
| Bloom Science | San Francisco, California, USA | 2019 | biotechtherapeutics+4 |
| Focal Biosciences | Boston, Massachusetts, USA | 2020 | biotechtherapeutics+3 |
| Refoxy Pharma | Berlin, Germany | 2020 | biotechtherapeutics+2 |
| Scripta Therapeutics | Boston, Massachusetts, USA | 2023 | biotechtherapeutics+2 |
| Galilei Biosciences | Boston, Massachusetts, USA | 2021 | biotechlongevity+3 |
| Ochre Bio | Oxford, United Kingdom & New York, USA | 2019 | biotechliver-disease+2 |
| ThymoFox | Berlin, Germany | 2020 | biotechimmunology+3 |
| YEARS | Berlin, Germany | 2021 | precision-medicinebiomarkers+3 |